Abstract 453P
Background
In terms of the clinical outcome and bad prognosis of cancer, the elevation in IL-6 levels is correlated with disease progression. It is believed that the post-vaccination effect increases the levels of IL-6 antagonists, which can slow the growth of cancer cells.
Methods
This research was conducted out on all cancer patients at Dr. Moewardi General Hospital using an observational analytical research design with a cross-sectional study, with a total sample of 120 patients who were divided into groups that had and had not received vaccination. IL-6 levels were measured using blood samples. To identify the correlation between IL-6 levels and COVID-19 vaccination status, we did descriptive analysis and the Chi-square test to examine the data results.
Results
There were 120 respondents in total, which all were processed for the analysis. out of 99 respondents who had full vaccination records. Then, 21 respondents who did not complete their vaccination status or receive the vaccine. Breast cancer is the most common cancer type in this population, which consists of 80 women and 40 males. Then, 59 respondents had increased Il-6 levels, whereas 61 respondents had normal levels. Findings of the research showed no statistically significant relationship between IL-6 levels and vaccination status (p>0.05).
Conclusions
IL-6 levels were used to analyze the relationship between vaccination status and cancer progression, and it was shown that participants who had received immunizations had no more impact on IL-6 levels than those who had not.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rico Alfredo Hutabarat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06